Kirsten Keller1, Martina Maass2, Sara Dizayee1, Veronika Leiss3, Suvi Annala1, Jessica Köth1, Wiebke K Seemann1, Jochen Müller-Ehmsen4, Klaus Mohr5, Bernd Nürnberg3, Stefan Engelhardt6, Stefan Herzig1, Lutz Birnbaumer7, Jan Matthes8. 1. Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany. 2. Department of Internal Medicine III, University Hospital of Cologne, Cologne, Germany. 3. Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, and Interfaculty Center of Pharmacogenomics and Drug Research, Tuebingen, Germany. 4. Asklepios Klinik Altona, Hamburg, Germany. 5. Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn, Bonn, Germany. 6. Institute of Pharmacology and Toxicology, Technische Universität München, Munich, Germany. 7. Laboratory of Neurobiology, NIEHS, NIH (Department of Health and Human Services), Durham, USA. 8. Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany jan.matthes@uni-koeln.de.
Abstract
AIMS: Inhibitory G (Gi) proteins have been proposed to be cardioprotective. We investigated effects of Gαi2 knockout on cardiac function and survival in a murine heart failure model of cardiac β1-adrenoceptor overexpression. METHODS AND RESULTS: β1-transgenic mice lacking Gαi2 (β1-tg/Gαi2 (-/-)) were compared with wild-type mice and littermates either overexpressing cardiac β1-adrenoceptors (β1-tg) or lacking Gαi2 (Gαi2 (-/-)). At 300 days, mortality of mice only lacking Gαi2 was already higher compared with wild-type or β1-tg, but similar to β1-tg/Gαi2 (-/-), mice. Beyond 300 days, mortality of β1-tg/Gαi2 (-/-) mice was enhanced compared with all other genotypes (mean survival time: 363 ± 21 days). At 300 days of age, echocardiography revealed similar cardiac function of wild-type, β1-tg, and Gαi2 (-/-) mice, but significant impairment for β1-tg/Gαi2 (-/-) mice (e.g. ejection fraction 14 ± 2 vs. 40 ± 4% in wild-type mice). Significantly increased ventricle-to-body weight ratio (0.71 ± 0.06 vs. 0.48 ± 0.02% in wild-type mice), left ventricular size (length 0.82 ± 0.04 vs. 0.66 ± 0.03 cm in wild types), and atrial natriuretic peptide and brain natriuretic peptide expression (mRNA: 2819 and 495% of wild-type mice, respectively) indicated hypertrophy. Gαi3 was significantly up-regulated in Gαi2 knockout mice (protein compared with wild type: 340 ± 90% in Gαi2 (-/-) and 394 ± 80% in β1-tg/Gαi2 (-/-), respectively). CONCLUSIONS: Gαi2 deficiency combined with cardiac β1-adrenoceptor overexpression strongly impaired survival and cardiac function. At 300 days of age, β1-adrenoceptor overexpression alone had not induced cardiac hypertrophy or dysfunction while there was overt cardiomyopathy in mice additionally lacking Gαi2. We propose an enhanced effect of increased β1-adrenergic drive by the lack of protection via Gαi2. Gαi3 up-regulation was not sufficient to compensate for Gαi2 deficiency, suggesting an isoform-specific or a concentration-dependent mechanism. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Inhibitory G (Gi) proteins have been proposed to be cardioprotective. We investigated effects of Gαi2 knockout on cardiac function and survival in a murineheart failure model of cardiac β1-adrenoceptor overexpression. METHODS AND RESULTS: β1-transgenic mice lacking Gαi2 (β1-tg/Gαi2 (-/-)) were compared with wild-type mice and littermates either overexpressing cardiac β1-adrenoceptors (β1-tg) or lacking Gαi2 (Gαi2 (-/-)). At 300 days, mortality of mice only lacking Gαi2 was already higher compared with wild-type or β1-tg, but similar to β1-tg/Gαi2 (-/-), mice. Beyond 300 days, mortality of β1-tg/Gαi2 (-/-) mice was enhanced compared with all other genotypes (mean survival time: 363 ± 21 days). At 300 days of age, echocardiography revealed similar cardiac function of wild-type, β1-tg, and Gαi2 (-/-) mice, but significant impairment for β1-tg/Gαi2 (-/-) mice (e.g. ejection fraction 14 ± 2 vs. 40 ± 4% in wild-type mice). Significantly increased ventricle-to-body weight ratio (0.71 ± 0.06 vs. 0.48 ± 0.02% in wild-type mice), left ventricular size (length 0.82 ± 0.04 vs. 0.66 ± 0.03 cm in wild types), and atrial natriuretic peptide and brain natriuretic peptide expression (mRNA: 2819 and 495% of wild-type mice, respectively) indicated hypertrophy. Gαi3 was significantly up-regulated in Gαi2 knockout mice (protein compared with wild type: 340 ± 90% in Gαi2 (-/-) and 394 ± 80% in β1-tg/Gαi2 (-/-), respectively). CONCLUSIONS: Gαi2 deficiency combined with cardiac β1-adrenoceptor overexpression strongly impaired survival and cardiac function. At 300 days of age, β1-adrenoceptor overexpression alone had not induced cardiac hypertrophy or dysfunction while there was overt cardiomyopathy in mice additionally lacking Gαi2. We propose an enhanced effect of increased β1-adrenergic drive by the lack of protection via Gαi2. Gαi3 up-regulation was not sufficient to compensate for Gαi2 deficiency, suggesting an isoform-specific or a concentration-dependent mechanism. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Michael T Reinartz; Solveig Kälble; Timo Littmann; Takeaki Ozawa; Stefan Dove; Volkhard Kaever; Irving W Wainer; Roland Seifert Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-10-24 Impact factor: 3.000
Authors: S B Liggett; N M Tepe; J N Lorenz; A M Canning; T D Jantz; S Mitarai; A Yatani; G W Dorn Journal: Circulation Date: 2000-04-11 Impact factor: 29.690
Authors: Caroline Bull Melsom; Rizwan Iqbal Hussain; Øivind Ørstavik; Jan Magnus Aronsen; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-09-13 Impact factor: 3.000
Authors: Caroline Bull Melsom; Øivind Ørstavik; Jan-Bjørn Osnes; Tor Skomedal; Finn Olav Levy; Kurt Allen Krobert Journal: PLoS One Date: 2014-09-09 Impact factor: 3.240